Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis
- PMID: 29410294
- DOI: 10.1016/j.juro.2017.11.136
Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis
Abstract
Purpose: Use of androgen deprivation therapy may increase the risk of cognitive impairment in men with prostate cancer. We performed a systematic review of the risk of overall cognitive impairment as an outcome in men receiving androgen deprivation therapy for prostate cancer.
Materials and methods: Studies were identified through PubMed®, MEDLINE®, PsycINFO®, Cochrane Library and Web of Knowledge/Science™. Articles were included if they 1) were published in English, 2) had subjects treated for prostate cancer with androgen deprivation therapy, 3) incorporated longitudinal comparisons and 4) used control groups. In addition, prospective studies were required to assess an established cognitive related end point using International Cognition and Cancer Task Force criteria defining impaired cognitive performance as scoring 1.5 or more standard deviations below published norms on 2 or more tests, or scoring 2.0 or more standard deviations below published norms on at least 1 test. The effect of androgen deprivation therapy on cognitive impairment was pooled using a random effects model.
Results: Of 221 abstracts 26 were selected for full text review, and 2 prospective and 4 retrospective studies were analyzed. Androgen deprivation therapy was not associated with overall cognitive impairment when the prospective cohort studies were pooled (OR 1.57, 95% CI 0.50 to 4.92, p = 0.44) with significant heterogeneity between estimates (I2 = 83%). In retrospective data the relative risk of any cognitive impairment, including senile dementia and Alzheimer disease, was increased in men receiving androgen deprivation therapy, although the difference was not statistically significant (HR 1.28, 95% CI 0.93 to 1.76, p = 0.13) with moderate heterogeneity between estimates (I2 = 67%).
Conclusions: Analyses between overall cognitive impairment and use of androgen deprivation therapy defined according to International Cognition and Cancer Task Force criteria in a pooled analysis were inconclusive. In retrospective cohort studies the risk of overall cognitive impairment after androgen deprivation therapy was not significant. Better prospective studies need to be designed for the assessment of this end point.
Keywords: Alzheimer disease; androgen antagonists; cognition; dementia; prostatic neoplasms.
Copyright © 2018 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Similar articles
-
The Risk of New Onset Dementia and/or Alzheimer Disease among Patients with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis.J Urol. 2021 Jan;205(1):60-67. doi: 10.1097/JU.0000000000001341. Epub 2020 Aug 28. J Urol. 2021. PMID: 32856962
-
Does hormone therapy impact cognition in patients with prostate cancer? A systematic review and meta-analysis.Cancer. 2024 Jun 15;130(12):2120-2138. doi: 10.1002/cncr.35210. Epub 2024 Feb 2. Cancer. 2024. PMID: 38306301
-
Impact of Androgen Deprivation Therapy on Self-Reported Cognitive Function in Men with Prostate Cancer.J Urol. 2018 Aug;200(2):327-334. doi: 10.1016/j.juro.2018.02.073. Epub 2018 Mar 1. J Urol. 2018. PMID: 29477720
-
Androgen-deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire?Cancer. 2018 Apr 1;124(7):1326-1334. doi: 10.1002/cncr.31153. Epub 2018 Jan 16. Cancer. 2018. PMID: 29338083 Free PMC article. Review.
-
Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.JAMA Oncol. 2015 Dec;1(9):1261-9. doi: 10.1001/jamaoncol.2015.2895. JAMA Oncol. 2015. PMID: 26378418 Review.
Cited by
-
The effect of estradiol add-back: a longitudinal MRI study in prostate cancer patients.Endocr Connect. 2024 Feb 7;13(3):e230409. doi: 10.1530/EC-23-0409. Print 2024 Mar 1. Endocr Connect. 2024. PMID: 38226639 Free PMC article.
-
Causal effects of genetically predicted testosterone on Alzheimer's disease: a two-sample mendelian randomization study.Acta Neurol Belg. 2024 Apr;124(2):591-601. doi: 10.1007/s13760-023-02426-4. Epub 2023 Nov 25. Acta Neurol Belg. 2024. PMID: 38007406
-
Male- and female-specific reproductive risk factors across the lifespan for dementia or cognitive decline: a systematic review and meta-analysis.BMC Med. 2023 Nov 23;21(1):457. doi: 10.1186/s12916-023-03159-0. BMC Med. 2023. PMID: 37996855 Free PMC article. Review.
-
A review of the objective cognitive function measurements in males receiving hormonal therapy for prostate cancer.Investig Clin Urol. 2023 Nov;64(6):521-540. doi: 10.4111/icu.20230103. Investig Clin Urol. 2023. PMID: 37932563 Free PMC article. Review.
-
Neurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4/6 inhibitors: a pharmacovigilance study using the World Health Organization's database.Front Pharmacol. 2023 Oct 20;14:1278682. doi: 10.3389/fphar.2023.1278682. eCollection 2023. Front Pharmacol. 2023. PMID: 37927591 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical